Mintz M.L. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors. J Fam Pract. 2016;65(12). pii: supp_az_1216. Available at: https://www.mdedge.com/content/role-kidney-type-2-diabetes-and-mechanism-action-sodium-glucose-cotransporter-2-inhibitors.https://www.mdedge.com/content/role-kidney-type-2-diabetes-and-mechanism-action-sodium-glucose-cotransporter-2-inhibitors
Mintz M.L. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors. J Fam Pract. 2016;65(12). pii: supp_az_1216. Available at: https://www.mdedge.com/content/role-kidney-type-2-diabetes-and-mechanism-action-sodium-glucose-cotransporter-2-inhibitors.https://www.mdedge.com/content/role-kidney-type-2-diabetes-and-mechanism-action-sodium-glucose-cotransporter-2-inhibitors
Сергиенко И.В., Бойцов С.А., Шестакова М.В., Салухов В.В. Кардиологические аспекты сахарного диабета 2 типа. СПб.: Фолиант; 2018. 64 с.
Bakris G.L., Sarafidis P.A., Weir M.R., Dahlöf B., Pitt B., Jamerson K. et al. Renal outcomes with different xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomized controlled trial. Lancet. 2010;375(9721):1173–1781. doi: 10.1016/S0140-6736(09)62100-0..
DOI: 10.1016/S0140-6736(09)62100-0
de Galan B.E., Perkovic V., Ninomiya T., Pillai A., Patel A., Cass A. et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20(4):883–892. doi: 10.1681/ASN.2008070667..
DOI: 10.1681/ASN.2008070667
Vaccaro O., Masulli M., Nicolucci A., Bonora E., Del Prato S., Maggioni A.P. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology. 2017;5(11):887–897. doi: 10.1016/S2213-8587(17)30317-0..
DOI: 10.1016/S2213-8587(17)30317-0
Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Кадин Д.В. Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований. Сахарный диабет. 2018;21(3):193–205. doi: 10.14341/DM9570..
DOI: 10.14341/DM9570
Abdul-Ghani M., Del Prato S., Chilton R., DeFronzo R.A. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care; 2016;39(5):717–725. doi: 10.2337/dc16-0041..
DOI: 10.2337/dc16-0041
Zelniker T.A., Braunwald E. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):435–447. doi: 10.1016/j.jacc.2019.11.036..
DOI: 10.1016/j.jacc.2019.11.036
Fitchett D., Zinman B., Wanner C., Lachin J.M., Hantel S., Salsali A. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–1534. doi: 10.1093/eurheartj/ehv728..
DOI: 10.1093/eurheartj/ehv728
Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925..
DOI: 10.1056/NEJMoa1611925
Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A. et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)- TIMI 58 trial. Am Heart J. 2018;200:83–89. doi: 10.1016/j.ahj.2018.01.012..
DOI: 10.1016/j.ahj.2018.01.012
Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M. et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744..
DOI: 10.1056/NEJMoa1811744
Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управ- ления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494–510. doi: 10.14341/DM8216..
DOI: 10.14341/DM8216
Шаронова Л.А., Вербовой А.Ф. Место глифлозинов в управлении сахар- ным диабетом 2 типа. Фарматека. 2019;26(4):105–110. doi: 10.18565/pharmateca.2019.4.105-110..
DOI: 10.18565/pharmateca.2019.4.105-110
Rhee J.J., Jardine M.J., Chertow G.M., Mahaffey K.W. Dedicated kidney disease‐ focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY. Diabetes Obes Metab. 2020;22(1):46–54. doi: 10.1111/dom.13987..
DOI: 10.1111/dom.13987
Салухов В.В., Котова М.Е. Основные эффекты, вызываемые ингибитора- ми SGLT2 у больных сахарным диабетом типа 2, и механизмы, которые их определяют. Эндокринология: новости, мнения, обучение. 2019;8(3):61–74. doi: 10.24411/2304-9529-2019-13007..
DOI: 10.24411/2304-9529-2019-13007
Dagogo-Jack S., Liu J., Eldor R., Amorin G., Johnson J., Hille D. et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–540. doi: 10.1111/dom.13116..
DOI: 10.1111/dom.13116
Mudaliar S., Polidori D., Zambrowicz B., Henry R.R. Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport. Diabetes Care. 2015;38(12):2344–2353. doi: 10.2337/dc15-0642..
DOI: 10.2337/dc15-0642
Terra S.G., Focht K., Davies M., Frias J., Derosa G., Darekar A. et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–728. doi: 10.1111/dom.12888..
DOI: 10.1111/dom.12888
Markham A. Ertugliflozin: First Global Approval. Drugs. 2018;78(4):513–519. doi: 10.1007/s40265-018-0878-6..
DOI: 10.1007/s40265-018-0878-6
Briand F., Mayoux E., Brousseau E., Burr N., Urbain I., Costard C. et al. Empagliflozin, via switching metabolism toward lipid utilization moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–2038. doi: 10.2337/db16-0049..
DOI: 10.2337/db16-0049
Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J. et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–219. doi: 10.1016/S2213-8587(13)70084-6..
DOI: 10.1016/S2213-8587(13)70084-6
Bilezikian J.P., Watts N.B., Usiskin K., Polidori D., Fung A., Sullivan D., Rosenthal N. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101(1):44–51. doi: 10.1210/jc.2015-1860..
DOI: 10.1210/jc.2015-1860
Rosenstock J., Frias J., Páll D., Charbonnel B., Pascu R., Saur D. et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequatelycontrolled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–529. doi: 10.1111/dom.13103..
DOI: 10.1111/dom.13103
Gallo S., Charbonnel B., Goldman A., Shi H., Huyck S., Darekar A., Lauring B., Terra S.G. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21(4):1027–1036. doi: 10.1111/dom.13631..
DOI: 10.1111/dom.13631
Ji L., Liu Y., Miao H., Xie Y., Yang M., Wang W. et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474–1482. doi: 10.1111/dom.13681..
DOI: 10.1111/dom.13681
Vlotides G., Mertens P.R. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2015;30(8):1272–1276. doi: 10.1093/ndt/gfu299..
DOI: 10.1093/ndt/gfu299
Hollander P., Liu J., Hill J., Johnson J., Jiang Z.W., Golm G. et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther. 2018;9(1):193–207. doi: 10.1007/s13300-017-0354-4..
DOI: 10.1007/s13300-017-0354-4
Miller S., Krumins T., Zhou H., Huyck S., Johnson J., Golm G. et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253–268. doi: 10.1007/s13300-017-0358-0..
DOI: 10.1007/s13300-017-0358-0
Pratley R.E., Eldor R., Raji A., Golm G., Huyck S.B., Qiu Y. et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–1120. doi: 10.1111/dom.13194..
DOI: 10.1111/dom.13194
Scheen A.J. Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type 2 diabetes. Clin Pharmacokinet. 2017;56(7):703–718. doi: 10.1007/s40262-016-0498-9..
DOI: 10.1007/s40262-016-0498-9
Grunberger G., Camp S., Johnson J., Huyck S., Terra S.G., Mancuso J.P. et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49–66. doi: 10.1007/s13300-017-0337-5..
DOI: 10.1007/s13300-017-0337-5
Cannon C.P., McGuire D.K., Pratley R., Dagogo-Jack S., Mancuso J., Huyck S. et al. Design and baseline characteristics of the evaluation of ertugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23. doi: 10.1016/j.ahj.2018.08.016..
DOI: 10.1016/j.ahj.2018.08.016